ExomeDNAExomeDNA
Read your report

COVID-19 Severity and Lupus Link and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: 2026-05-29

For informational purposes only. Consult a healthcare provider for clinical guidance.

At first glance, COVID-19 hospitalization and systemic lupus erythematosus (SLE) seem like an unlikely pairing. One is caused by a novel coronavirus; the other is a chronic autoimmune disease in which the immune system attacks the body's own tissues. Yet genome-wide research has revealed that both conditions draw on overlapping segments of the immune genome — particularly genes involved in interferon signaling, complement regulation, and immune cell chemotaxis. This shared genetic architecture is the biological basis for the ExomeDNA trait called COVID-19 Severity and Lupus Link.

Systemic lupus erythematosus affects approximately 5 million people worldwide, with a strong female predominance and heightened prevalence in populations of African, Asian, and Hispanic descent. It is characterized by systemic inflammation, autoantibody production, and organ involvement that can range from skin and joints to kidneys and the central nervous system. COVID-19, caused by SARS-CoV-2, emerged as a global pandemic in 2020 and has caused millions of hospitalizations worldwide. Severe COVID-19 is associated with a dysregulated immune response — sometimes called a cytokine storm — that bears mechanistic resemblance to lupus flares.

The multi-trait analysis group (MTAG) methodology used in PMID 36762574 leverages genetic summary statistics from multiple related phenotypes simultaneously to boost the power to detect shared loci. By treating COVID-19 hospitalization risk and SLE susceptibility as genetically correlated traits, this approach identifies genetic variants that influence both — providing a window into shared immune regulatory pathways.

~5 million people worldwide live with systemic lupus erythematosus, a chronic autoimmune condition with genetic overlap with severe COVID-19 responses.[1]

The genetic underpinnings of this combined trait converge on a set of immune regulatory genes with clear biological relevance to both viral defense and autoimmune control.

CCR1 (chromosome 3, rank 1, L2G score 0.84) encodes C-C chemokine receptor type 1, expressed on monocytes, macrophages, and neutrophils. CCR1 mediates cell migration in response to inflammatory chemokines including CCL3, CCL5, and CCL7. In the context of COVID-19, monocyte and macrophage recruitment to the lungs is a key driver of severe disease. In lupus, dysregulated monocyte trafficking contributes to tissue damage. CCR1's position at the top of the genetic ranking makes it a compelling candidate mediating both phenotypes.

IRF5 (chromosome 7, rank 2, L2G score 0.75) encodes interferon regulatory factor 5, a transcription factor that drives type I interferon production and pro-inflammatory cytokine programs. IRF5 has long been one of the most robustly implicated genes in lupus genetics, with the rs2004640 variant among the most replicated SLE associations. In COVID-19 severity, dysregulated interferon signaling is mechanistically central — early type I interferon responses protect against SARS-CoV-2, while excessive IRF5-driven inflammation at later stages contributes to severe outcomes.

CCR3 (chromosome 3, rank 3) encodes a related chemokine receptor, expressed primarily on eosinophils. The protein encoded by CCR3 binds and responds to chemokines including eotaxin and plays roles in allergic and eosinophilic inflammation. Its proximity to CCR1 in the same genomic locus reflects a cluster of chemokine receptor genes with coordinated immune functions.

FUT2 (chromosome 19, rank 4) encodes fucosyltransferase 2, an enzyme responsible for the secretor phenotype — determining whether ABO blood group antigens are secreted in body fluids. FUT2 variation influences susceptibility to several viral infections including norovirus and rotavirus, and has been implicated in gut microbiome composition. Its appearance in an autoimmune/COVID-19 GWAS reflects the increasingly recognized role of mucosal immunity and the secretor status in viral and immune phenotypes.

Additional ranked genes include ADAM15 (a metalloproteinase involved in cell adhesion and migration), CCHCR1 (a coiled-coil protein involved in mRNA metabolism), and HLA-DQA1 and HLA-DQB1 from the central HLA region — critical for immune antigen presentation.

IRF5 and CCR1 are among the most consistently implicated genes in lupus genetics and both carry mechanistic relevance to the dysregulated immune responses seen in severe COVID-19.[1]

What the research says

The foundational study for this trait (PMID 36762574) applied multi-trait analysis group (MTAG) methodology to combine GWAS summary statistics from COVID-19 hospitalization and SLE. This statistical approach capitalizes on genetic correlation between phenotypes to increase effective sample size without requiring individual-level data sharing — a methodological advantage that has proven valuable for rare or severe phenotypes where large case cohorts are difficult to assemble.

For a detailed explanation of how ExomeDNA evaluates genetic association evidence and translates GWAS findings, see our methodology page.

The broader literature connecting lupus biology to COVID-19 outcomes is growing. Early clinical observations noted that lupus patients showed heterogeneous COVID-19 outcomes — some appeared protected by pre-existing hydroxychloroquine use, while others with active disease had elevated risk of severe illness. Mechanistically, the interferon axis sits at the center of both: SLE is characterized by constitutive type I interferon activation, while early SARS-CoV-2 infection requires a robust interferon response that later, in severe cases, gives way to a pro-inflammatory cytokine environment. IRF5 is a key node in both pathways.

This moderate-confidence trait reflects one primary GWAS study. The MTAG approach provides meaningful signal, and the genes identified have strong biological plausibility, but additional studies in diverse populations are needed to fully characterize the shared genetic architecture.

For anyone reviewing this trait, the practical context matters. This genetic signal does not reflect risk for COVID-19 infection per se — it captures variants associated with the severity of response, particularly hospitalization risk, in conjunction with lupus susceptibility pathways. Most people who encounter SARS-CoV-2 do not require hospitalization; the genetics captured here relate to the immune regulatory pathways that influence whether mild illness escalates.

For people with personal or family histories of autoimmune disease — particularly lupus, but also related conditions like Sjogren's syndrome, undifferentiated connective tissue disease, or mixed connective tissue disease — this result may hold particular relevance. Lupus itself is a condition with highly variable clinical trajectories: some individuals have relatively mild, skin-limited disease; others develop serious nephritis or neuropsychiatric manifestations. Genetic susceptibility influences this landscape but does not determine it.

In the context of COVID-19 specifically, vaccination remains the most evidence-supported public health intervention for reducing hospitalization risk, regardless of genetic background. Standard recommendations around staying current with vaccine schedules apply universally.

For lupus susceptibility specifically, the practical clinical implications of elevated genetic scores are similar to other autoimmune traits: awareness, symptom monitoring (unexplained rashes, joint pain, fatigue, protein in urine), and timely consultation with a rheumatologist if symptoms arise. Lupus can be effectively managed with a combination of antimalarials, immunosuppressants, and targeted biologics when appropriate clinical assessment leads to timely intervention.

Working with your profile

A genetic result on this trait reflects your inherited pattern of variation across the shared COVID-19 severity and lupus susceptibility loci identified by MTAG analysis. It is not a personal health forecast or a clinical screening result.

For anyone seeking to contextualize this result:

First, understand what the genetic signal captures. MTAG-derived associations reflect shared genetic architecture across two phenotypes. The specific contribution to each individual phenotype — COVID-19 severity versus lupus susceptibility — cannot be cleanly separated at the individual level from this combined signal.

Second, be aware that lupus is a clinically heterogeneous condition with strong sex and ancestry influences that go beyond genetics. Women of reproductive age from African and Hispanic populations are disproportionately affected. Genetic risk variants captured in GWAS studies of predominantly European populations may perform differently across ancestry groups.

Third, if autoimmune symptoms are present — unexplained fatigue, photosensitive rashes, joint inflammation, hair loss, kidney abnormalities, or recurrent serositis — bring this to a rheumatologist's attention. Lupus is notoriously difficult to identify clinically due to symptom variability; a rheumatologist can perform appropriate antibody panels (ANA, anti-dsDNA, complement levels) and clinical assessment.

Finally, this result reflects the current state of genetic science. The COVID-19 genetics literature evolved rapidly during and after the pandemic, and our understanding of genetic contributors to severe COVID-19 and their intersection with autoimmune biology continues to develop.

The COVID-19 severity and lupus link trait sits within the broader cluster of immune and autoimmune traits on ExomeDNA. Closely related profiles include lupus susceptibility, rheumatoid arthritis or MS autoimmune susceptibility, inflammatory bowel disease, and complement system activity — all of which draw on overlapping HLA and immune-regulatory genetic architecture.

The chemokine receptor cluster on chromosome 3 — which includes CCR1, CCR3, and related genes — appears across multiple immune traits, reflecting the shared biology of immune cell trafficking in infections, inflammation, and autoimmunity. IRF5 is perhaps the most cross-cutting gene in this neighborhood; its associations with lupus, inflammatory bowel disease, rheumatoid arthritis, and now COVID-19 severity illustrate how interferon regulatory pathways sit at the genetic nexus of many immune conditions.

FUT2 adds an intriguing dimension: its role in the secretor phenotype links this autoimmune/COVID-19 locus to mucosal immunity and susceptibility to viral pathogens that enter through mucosal surfaces. This connection suggests that the gut-immune axis may be a relevant pathway for understanding the shared biology of this trait cluster.

Additional genes in this trait's landscape — ADAM15, CCHCR1, and HLA-DQA1 — are relevant across a range of autoimmune and immune-mediated phenotypes. ADAM15 is involved in cell adhesion events relevant to inflammatory cell trafficking; CCHCR1 has been implicated in inflammatory skin conditions; HLA-DQA1 and HLA-DQB1 are central to antigen presentation for adaptive immune responses across virtually all autoimmune conditions.

Frequently asked questions

Q: Does this result tell me whether I am more likely to be hospitalized if I get COVID-19? A: This result reflects genetic variants associated with COVID-19 hospitalization risk in population-level GWAS analyses, studied in conjunction with lupus susceptibility. It is not an individual-level forecast of hospitalization probability. Vaccination status, age, underlying health conditions, and access to timely care are all major determinants of COVID-19 outcomes at the individual level.

Q: Could this result mean I am more likely to develop lupus? A: This trait reflects genetic variants associated with lupus susceptibility as part of a multi-trait GWAS. Elevated signals indicate increased population-level association with lupus-related loci, but do not constitute a personal clinical assessment. Many individuals with elevated polygenic scores never develop lupus, and the condition involves complex interactions between genetics, hormones, environment, and immune history.

Q: What is MTAG and why does it matter for this trait? A: Multi-trait analysis group (MTAG) is a statistical method that combines GWAS summary statistics from multiple genetically correlated traits to boost statistical power. For this trait, MTAG combined COVID-19 hospitalization and SLE data, allowing detection of shared genetic loci that might not reach significance in studies of either condition alone. It is particularly useful for severe phenotypes where large case cohorts are hard to assemble.

Q: How are CCR1 and IRF5 connected to both COVID-19 and lupus? A: CCR1 regulates the migration of immune cells such as monocytes and macrophages — central to both the lung inflammation seen in severe COVID-19 and the tissue damage seen in lupus. IRF5 drives type I interferon production and pro-inflammatory cytokine programs; it is a key node in both SARS-CoV-2 defense and the constitutive interferon activation characteristic of lupus. Both genes represent convergence points in immune regulation.

Q: Is there anything specific people with lupus should know about COVID-19? A: People living with lupus should discuss COVID-19 vaccination with their rheumatologist, as immunosuppressive medications may affect vaccine responses. Staying current with vaccine schedules is generally recommended. Those with active disease or on high-dose immunosuppression may have specific considerations — this is a conversation for a treating physician rather than a genetic report.

References

  1. PMID 36762574 — Multi-trait GWAS of COVID-19 hospitalization and systemic lupus erythematosus.

This page is for educational purposes only. ExomeDNA does not provide clinical guidance. For health-related questions, please consult a qualified healthcare provider.

[FDA Wellness Compliance Footer — content from legal/fda-wellness-footer.md]

Browse all traits →